Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Collazo-Lorduy

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Genes & Development|August 1, 2015
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancersRuth Rodriguez-Barrueco, Jiyang Yu, Laura P Saucedo-Cuevas, et al.
Acta Oncologica (Stockholm, Sweden)|August 9, 2020
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumabAlex Friedlaender, Giulio Metro, Diego Signorelli, et al.
Journal of Thoracic Disease|February 8, 2020
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohortGiulio Metro, Alfredo Addeo, Diego Signorelli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
Cancers|August 27, 2021
A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative AnalysisMaría Sereno, Ana María Jimenez-Gordo, Javier Baena-Espinar, et al.
Biomarker Research|May 21, 2026
Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancerMarta Molina-Alejandre, Cristina Martínez-Toledo, Belén Sierra-Rodero, et al.
Pharmacological Research|May 7, 2026
Early Pembrolizumab Plasma Levels as a Prognostic Biomarker in Real-World NSCLC PatientsCristina Martínez-Toledo, María Jiménez-Meseguer, Marta Molina-Alejandre, et al.
Lung Cancer (Amsterdam, Netherlands)|June 30, 2024
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLCMariano Provencio, Lucía Robado de Lope, Roberto Serna-Blasco, et al.
Translational Lung Cancer Research|March 4, 2022
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID studyMariano Provencio, Delvys Rodríguez-Abreu, Ana L Ortega, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Genes & Development|August 1, 2015
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancersRuth Rodriguez-Barrueco, Jiyang Yu, Laura P Saucedo-Cuevas, et al.
Acta Oncologica (Stockholm, Sweden)|August 9, 2020
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumabAlex Friedlaender, Giulio Metro, Diego Signorelli, et al.
Journal of Thoracic Disease|February 8, 2020
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohortGiulio Metro, Alfredo Addeo, Diego Signorelli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
Cancers|August 27, 2021
A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative AnalysisMaría Sereno, Ana María Jimenez-Gordo, Javier Baena-Espinar, et al.
Biomarker Research|May 21, 2026
Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancerMarta Molina-Alejandre, Cristina Martínez-Toledo, Belén Sierra-Rodero, et al.
Pharmacological Research|May 7, 2026
Early Pembrolizumab Plasma Levels as a Prognostic Biomarker in Real-World NSCLC PatientsCristina Martínez-Toledo, María Jiménez-Meseguer, Marta Molina-Alejandre, et al.
Lung Cancer (Amsterdam, Netherlands)|June 30, 2024
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLCMariano Provencio, Lucía Robado de Lope, Roberto Serna-Blasco, et al.
Translational Lung Cancer Research|March 4, 2022
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID studyMariano Provencio, Delvys Rodríguez-Abreu, Ana L Ortega, et al.
Pageof 4